ANAVEX LIFE SCIENCES CORP. AVXL
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
1/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$46.4M | — | — | $94.9M |
| 2024 | — | -$43.0M | — | — | $120.3M |
| 2023 | — | -$47.5M | — | — | $141.9M |
| 2022 | — | -$48.0M | — | — | $142.5M |
| 2021 | — | -$37.9M | — | — | $150.8M |
| 2020 | — | -$26.3M | — | — | $27.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| MISSLING CHRISTOPHER U | President and CEO | 2025-09-11 | Option exercise | 187,500 | $5.04 |
| MISSLING CHRISTOPHER U | President and CEO | 2025-09-11 | Tax withheld | 145,048 | $9.58 |
| Thomas Steffen | director | 2025-06-05 | Option exercise | 50,000 | $1.76 |
| Thomas Steffen | director | 2025-06-05 | Tax withheld | 11,349 | $7.75 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Source: SEC EDGAR filings · CIK 0001314052 · as of 2025-09-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.